KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.

J Am Heart Assoc · 2025-Nov-04 · PMID 41128134

Panel C质量警告待 EXE 对齐验证

Net clinical benefit

Figure 2. Net clinical benefit of the VOYAGER PAD efficacy and safety outcomes. Outcomes using various combined efficacy and safety end points at 3 years, comparing rivaroxaban to placebo. All analyses included myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation. A , Included cardiovascular death and intracranial or fatal bleeding. B , Included cardiovascular death and TIMI major bleeding. C , Included all‐cause death and intracranial or fatal bleeding. D , Included all‐cause death and TIMI major bleeding. ASA indicates acetylsalicylic acid (aspirin); TIMI indicates thrombolysis in myocardial infarction; and VOYAGER PAD, Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.79
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T17:58:47+00:00